The information on this page is intended for journalists, press and media. Click YES to get to the newsroom. If you click NO you will come back to Mynewsdesk.com.
Three clinical studies have concluded that a new and ground-breaking monitoring system using artificial intelligence and wireless technology to monitor patients can identify clinical deterioration earlier than currently used “manual and simplistic” methods.Researchers from the WARD project (Wireless Assessment of Respiratory and circulatory Distress) at Rigshospitalet, Bispebjerg Hospital and
Isansys Lifecare, a global leader in digital healthcare and AI applications, today announced it has received UKCA Full Quality Assurance Certification for its clinical wearable sensors and continuous patient monitoring platform, the Patient Status Engine (PSE). This important milestone is a first for a UK company and will ensure that patients, hospitals, and other healthcare providers across the U
Isansys Lifecare, a company dedicated to improving lives with the use of technology, has become one of the first wireless patient monitoring manufacturers to successfully achieve certification of its quality management system (QMS) under the new Medical Device Regulation (MDR) (EU 2017/745 ) now in force in the European Union (EU). The EU MDR certificate has been issued for the Patient Status
The Alder Hey Children’s NHS Foundation Trust and Isansys Lifecare have won funding from NHS England’s Transformation Directorate (formally NHSX) to create a hospital from home for acutely unwell children. Alder Hey Children’s NHS Foundation Trust, Liverpool, UK, has successfully trialled the state-of-the-art Patient Status Engine (PSE), a wireless patient monitoring system developed by Isansy
A world-leading children’s hospital has partnered with digital healthcare pioneers Isansys Lifecare as part of a trial to support at home patient monitoring and reduce pressures on the healthcare system.The collaboration will see Alder Hey Children’s NHS Foundation Trust, Liverpool, UK, making use of the state-of-the-art Patient Status Engine (PSE) - wireless patient monitoring system - as par
Isansys Lifecare has won the title of Best Established Medtech Company at the prestigious 2021 OBN Awards.The company, based in Oxfordshire, was recognised for the development of its Patient Status Engine (PSE), an advanced remote patient monitoring platform that collects and analyses patients’ vital signs and helps inform healthcare decisions.The technology enables timely interventions th
For many people the social restrictions experienced during lockdowns will have had long-lasting consequences, increasing feelings of loneliness, stress and depression.But throughout the pandemic those employed in hospitals and care settings have faced the same issues, alongside having to deal with the pressures of working on the front-line.Covid-19 has stretched medical staff to their limi
Isansys Lifecare will find out next month if it has won the title of Best Established Medtech Company at the prestigious 2021 OBN Awards.The company, based in Oxfordshire, was shortlisted for the development of its Patient Status Engine (PSE), an advanced patient monitoring platform that collects and analyses patients’ vital signs and helps inform healthcare decisions. The PSE represents a
Digital transformation is not about new products, systems or processes. Fundamentally it's about a new way of caring
Isansys Lifecare has been named as one of the top 20 medtech companies in the UK. BusinessCloud’s inaugural Medtech 50 ranking celebrates the country’s most innovative start-ups, scaleups and established firms developing technologies to help diagnose and treat existing conditions – mostly in a hospital or clinical setting – and other biotechnology companies.Hundreds of companies were short
Top clinician at a leading UK children’s hospital believes the future of healthcare involves wireless monitoring and smart alarms, both in hospital and at home
Rigorous clinical validation of AI and machine learning technologies is vital to ensure devices are fit for clinical use
When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.
To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.
Please note that our Terms of Use apply to all use of our services.
You can withdraw your consent at any time by unsubscribing or deleting your account.
Email sent to __email__. Click the link there to follow Isansys.